Vivek Ramaswamy eyes an I/O vant with up to $2B licensing deal
Has Vivek Ramaswamy found the seed of his next vant?
On Monday, Roivant announced a rare partnership deal, signing an agreement with the German immuno-oncology small-cap Affimed worth $60 million upfront and up to $2 billion in milestones. For all the company’s sprawling tentacles, it’s the first time since their 2018 pact with Daiichi Sankyo that Roivant itself has announced a licensing agreement with another developer and one of the largest deals, in terms of biobucks, they’ve ever disclosed.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.